 CAMBRIDGE, Mass., March 8, 2022 PRNewswire -- Nuvalent, Inc., Nasdaq: NUVL a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced multiple preclinical data presentations supporting advancement of its parallel lead programs including NVL-520 a ROS1-selective inhibitor and NVL-655 an ALK-selective inhibitor. 